MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) began an open-label, U.S. Phase I trial to evaluate escalating doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive cancers who have failed prior therapies.

The trial’s primary endpoints are maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and safety. Secondary endpoints include pharmacokinetics, recommended Phase II dose, duration of response and antibodies...